Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for severe tophaceous gout
NL-OMON27662Not yet recruiting
- Sponsor
- Sanofi
- Start
- May 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of rasburicase in gout, sponsored by Sanofi. Primary endpoint: Serum uric acid concentration. Planned start May 2021; status: not yet recruiting.
02
Drugs
rasburicase
03
Conditions
gout
Beyond the preview
Go deeper on NL-OMON27662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27662.